Health Education Answer Note #2

Question 1 Make a project on topic- ASTRAZENECA’S COVISHIELD as an effective vaccine against CORONA VIRUS (Key points: Launch of vaccine ,Need of the hour ,limited testing of vaccine before administration ,side effects and their long term complications, frequency of occurrence of side effects in terms of number of patients, life threatening therapeutic effects) Each key point should have more than 300 words Answer product-information-section Question 2 Targeted therapies are used in patients with a set gene expression pattern. A targeted therapy that prevents the activation of the estrogen receptor in breast cancer would be beneficial to which type of patient? A. patients with lots of the estrogen receptor expressed in their tumor B. patients that have no estrogen receptor expressed in their tumor C. patients who express the EGFR receptor in normal cells D. patients with a mutation that inactivates the estrogen receptor Answer q6 Lastly, patients with a mutation that inactivates the estrogen receptor, option D, may not benefit from this targeted therapy as it targets the activation of the estrogen receptor. Therefore, a mutation that inactivates the receptor would not be affected by this therapy. Question 3 Make a project on topic- ASTRAZENECA’S COVISHIELD as an effective vaccine against CORONA VIRUS (Key points: Launch of vaccine ,Need of the hour ,limited testing of vaccine before administration ,side effects and their long term complications, frequency of occurrence of side effects in terms of number of patients, life threatening therapeutic effects) Each key point should have more than 300 words Answer product-information-section Question 4 Targeted therapies are used in patients with a set gene expression pattern. A targeted therapy that prevents the activation of the estrogen receptor in breast cancer would be beneficial to which type of patient? A. patients with lots of the estrogen receptor expressed in their tumor B. patients that have no estrogen receptor expressed in their tumor C. patients who express the EGFR receptor in normal cells D. patients with a mutation that inactivates the estrogen receptor Answer q7 In conclusion, a targeted therapy that prevents the activation of the estrogen receptor in breast cancer would be beneficial for patients with breast cancer subtypes that express high levels of estrogen receptors, such as the luminal A or B subtypes. This approach highlights the importance of personalized medicine and the use of targeted therapies in the treatment of breast cancer patients.